Tison N, Bouchard E, DesCôteaux L, Lefebvre R C
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada.
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada.
Theriogenology. 2017 Feb;89:305-317. doi: 10.1016/j.theriogenology.2016.09.007. Epub 2016 Sep 29.
The objective of this study was to assess the efficacy of cephapirin intrauterine treatment preceding a timed artificial insemination protocol in lactating dairy cows with purulent vaginal discharges (PVDs). Holstein dairy cows (n = 1247) from 18 herds were enrolled in a controlled randomized clinical trial. At 34 days in milk (DIM; ±7 days), cows had a genital examination (transrectal palpation, vaginoscopy, and uterine bacteriology). They were randomly assigned to either the control group (CONT, no treatment) or the treatment group (CEPH) consisting of 1 intrauterine infusion of 500-mg cephapirin benzathine (RCL) (Metricure, Merck Animal Health, Montreal, Canada) regardless of the uterine health status. All cows were systematically enrolled in a presynch-ovsynch protocol for the first insemination. A second genital examination was made 2 weeks later. Cows that received any systemic or local antibiotics 10 days prior sampling to the end of the synchronization protocol were excluded from the study. Reproductive data of cows were collected for at least 300 DIM, entered in a databank, and validated (health record management software, DSAHR). Pregnancy diagnosis was done by transrectal palpation at the routinely scheduled veterinarian visits. On the basis of the highest sum of sensibility and specificity for pregnancy status at 120 DIM, the optimal cutoff for vaginal discharge score was determined as the presence of cloudy discharge with or without purulent material (PVD+, score 2). With a prevalence of 21.6% at 34 DIM, PVD+ was detrimental to the first-service conception rate (FSCR; PVD+: 26 ± 5%; PVD-: 40 ± 3%; P = 0.02). The negative effect of PVD+ was indicated by a hazard ratio of 0.72 (chi-square = 8.58; P < 0.01; 95% confidence interval = 0.56-0.91). Treatment with cephapirin was associated with a significant improvement of the FSCR in PVD+ cows (PVD+ CEPH: 36 ± 5%, PVD+ CONT: 23 ± 5%; P < 0.05), although it did not produce a considerable clinical cure based on the second examination. Thus, a longer period of time following treatment may be needed to properly assess the efficacy of intrauterine treatment in PVD+ cows. In conclusion, cephapirin intrauterine treatment in PVD+ cows at 34 DIM considerably improves reproductive performance compared with untreated PVD+ cows.
本研究的目的是评估在定时人工授精方案之前,对患有脓性阴道分泌物(PVD)的泌乳奶牛进行头孢匹林宫内治疗的疗效。来自18个牛群的1247头荷斯坦奶牛被纳入一项对照随机临床试验。在产奶34天(DIM;±7天)时,对奶牛进行生殖系统检查(直肠触诊、阴道镜检查和子宫细菌学检查)。无论子宫健康状况如何,将它们随机分为对照组(CONT,不治疗)或治疗组(CEPH),治疗组进行1次宫内输注500毫克苄星头孢匹林(RCL)(Metricure,默克动物保健公司,加拿大蒙特利尔)。所有奶牛都系统地参加了预同步-排卵同步方案以进行首次人工授精。2周后进行第二次生殖系统检查。在同步方案结束前10天接受任何全身或局部抗生素治疗的奶牛被排除在研究之外。收集奶牛至少300天的生殖数据,输入数据库并进行验证(健康记录管理软件,DSAHR)。在常规安排的兽医就诊时通过直肠触诊进行妊娠诊断。根据120天妊娠状态的敏感性和特异性总和最高,将阴道分泌物评分的最佳临界值确定为存在浑浊分泌物,无论有无脓性物质(PVD+,评分2)。在34天DIM时,PVD+的患病率为21.6%,对首次输精受胎率(FSCR)有不利影响(PVD+:26±5%;PVD-:40±3%;P = 0.02)。PVD+的负面影响通过风险比0.72表明(卡方 = 8.58;P < 0.01;95%置信区间 = 0.56 - 0.91)。头孢匹林治疗使PVD+奶牛的FSCR有显著改善(PVD+ CEPH:36±5%,PVD+ CONT:23±5%;P < 0.05),尽管根据第二次检查并未产生明显的临床治愈效果。因此,可能需要更长的治疗后时间来正确评估宫内治疗对PVD+奶牛的疗效。总之,与未治疗的PVD+奶牛相比,在34天DIM时对PVD+奶牛进行头孢匹林宫内治疗可显著提高繁殖性能。